


*IFW*



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**1662/63202**

Application Number  
**10/781,543**

Filing Date  
**February 17, 2004**

Examiner  
**To be assigned**

Art Unit  
**1614**

Invention Title  
**MENTHOL SOLUTIONS OF DRUGS**

Inventor(s)  
**FLASHNER-BARAK et al.**

Address to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: *12/20/04*

Signature: *Kathy Fall*

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Supplemental Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. In accordance with the Official Gazette of August 5, 2003, which stated that the United States Patent and Trademark Office waived the requirement under 37 C.F.R. § 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications filed after June 30, 2003, copies of each of the cited U.S. patents and U.S. patent application publications are not being provided.
3. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
4. A copy of an International Search Report (ISR) recently received in a corresponding PCT application is also enclosed.
5. Applicant's attorney certifies that each item of information contained in the information disclosure statement was first cited in the International Search Report (copy attached) from PCT office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.
6. It is believed that no fees are due in connection with this Supplemental Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. **11-0600** for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 12/20/04

By: Craig L. Puckett  
Craig L. Puckett (Reg. No. 43,023)

**CUSTOMER NUMBER 26646**

**KENYON & KENYON**  
One Broadway  
New York, New York 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	ATTY. DOCKET NO. 1662/63202	SERIAL NO. 10/781,543
	APPLICANT FLASHNER-BARAK et al.	
	FILING DATE February 17, 2004	GROUP 1614

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 96/40192	December 19, 1996	PCT				
	WO 03/082247	October 9, 2003	PCT				

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	S. Nazzal et al., "Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation", Int. J. of Pharmaceutics (Kidlington), Vol. 235, No. 1-2, Pages 247-265, (2002)
	P. W. Stott et al., "Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen", J. of Controlled Release, Vol. 50, No. 1-3, pages 297-308, (1998)
	L. Kang et al., "Physicochemical studies of lidocaine-menthol binary systems for enhanced membrane transport", Int. J. of Pharmaceutics (Kidlington), Vol. 206, No. 1-2, Pages 35-42, (2000)
	Y. Kaplun-Frischoff et al., "Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids", J. of Pharmaceutical Sciences, Vol. 86, No. 12, Pgs. 1394-1399, (1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	